The most useful thing to know about NAD+ side effects is that the ones people actually encounter are mostly tied to how fast it is given rather than how much. That single fact explains most of what gets reported, and it is also the most fixable.
This page is general information, not medical advice. If you are experiencing symptoms after receiving any injectable product, contact your prescribing clinician. Adverse reactions can be reported to FDA MedWatch at 1-800-332-1088.
The infusion rate effect
With intravenous NAD+, a recognisable cluster of sensations is commonly reported during administration, particularly when the drip runs quickly:
- Chest tightness or pressure
- Flushing and a feeling of warmth
- Nausea
- Abdominal cramping
- Headache
- Lightheadedness
- A sense of urgency or restlessness
These are typically described as coming on during the infusion and easing when the rate is slowed or paused. Slowing the drip is the standard response, which is why supervised IV administration is normally given over a longer period rather than pushed.
This is the reason IV NAD+ sessions take as long as they do. It is not padding the appointment.
Reported effects by route
| Route | More commonly reported |
|---|---|
| Intravenous | The infusion rate cluster above. Discomfort at the cannula site |
| Subcutaneous injection | Injection site redness, tenderness, swelling or bruising. Nausea and headache reported less often than with IV |
| Nasal spray | Nasal irritation, stinging, running nose, taste disturbance |
Because there is no FDA approved NAD+ product, there is no approved label listing adverse reactions with frequencies. Everything above is drawn from clinical reports and practice rather than from controlled safety data, and it is less complete than a drug label would be. That gap is worth knowing about in itself.
The risk that is not about the molecule
As with any injectable, a serious category of risk comes from what is in the vial besides the active ingredient.
In August 2026 FDA reminded compounders that they “should not use dietary supplement grade ingredients when making injectable drugs”, warning that supplement grade material “may contain impurities and contaminants, including endotoxins, that may be harmful when administered as an injectable drug.” At least 30 patients had adverse events, some requiring hospitalisation, from injectable material sourced this way. That alert concerned glutathione, and the principle applies to every compounded injectable including NAD+.
Fever and chills beginning within hours of a dose are the pattern that should prompt a call to your clinician, because that is contamination rather than a typical drug effect. Full detail is in glutathione side effects and the sourcing question.
Who should be cautious
- Anyone with a cardiac history should raise the chest tightness effect specifically before a first infusion, so it is not mistaken for something else in the moment.
- Anyone who is pregnant or breastfeeding. There is not adequate data to support use.
- Anyone on other medications. Disclose everything at intake, including supplements.
- Anyone with a history of significant reactions to injectables.
When to seek help
Seek medical attention promptly for difficulty breathing, swelling of the face, lips or throat, hives, chest pain that does not settle when an infusion is stopped, or fainting. Contact your prescribing clinician for fever or chills after a dose, a spreading injection site reaction, or persistent vomiting.
Keeping it in proportion
Most of what is reported is transient, tied to infusion rate, and resolves by slowing down. The serious risks are the ones common to all compounded injectables, and they are addressable by asking about grade, pharmacy and lot testing before you start.
Wider context is in the NAD+ therapy guide, dosing factors in NAD+ dosage, and the regulatory position in is NAD+ FDA approved.
Sources
Every quotation attributed to the FDA on this page is taken from the documents below. Follow the links and check them.
- FDA, FDA reminds compounders not to use dietary supplement grade glutathione for injectables. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-not-use-dietary-supplement-grade-glutathione-injectables
- FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- FDA MedWatch, Safety Information and Adverse Event Reporting Program. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
Last reviewed 9 September 2026. Regulatory status in compounding changes. If you are reading this well after that date, check the FDA sources directly rather than relying on this page.
Related reading
- The FDA peptide compounding status tracker, kept current
- NAD+ therapy: the complete guide
- NAD+ IV versus injection versus nasal spray
- Is NAD+ FDA approved?
- NAD+ injections and what the evidence covers
- NAD+ dosage and what determines it
- NAD+ nasal spray
- BPC-157
- Glutathione therapy: the complete guide
- Peptide reconstitution calculator
Longevity plans from PrescribedRX
PrescribedRX prescribes longevity treatments through clinicians licensed in your state:
- Glutathione Injection. Administered by injection after a provider consultation.
- Glutathione Nasal Spray. A nasal alternative.
- NAD+ Injections. On a schedule set by your provider.
- NAD+ Nasal Spray. A nasal alternative.
- Sermorelin Injections. By prescription after consultation.
Every plan and its current price is on the plans page and the pricing page.
These are compounded preparations. Compounded drugs are not reviewed or approved by the FDA for safety or effectiveness, and treatment outcomes are not guaranteed.
This article is for general information. It is not medical advice and it is not a recommendation for any particular treatment. Whether a treatment is appropriate for you is a decision for a licensed clinician who has reviewed your health history and current medications.
